Aptar Digital Health announced a strategic partnership with Enable Injections to develop a companion digital solution for the enFuse On-Body Delivery System. The collaboration designates Aptar Digital Health as Enable's preferred digital health partner for the injection device system.

The digital solution will guide patients and caregivers through the injection process and provide support before, during and after medication administration. Key features include treatment data recording, onboarding modules, injection guidance, patient-reported outcomes tracking and symptom monitoring.

Built on a scalable architecture, the companion solution will be deployed alongside the enFuse system to enable pharmaceutical partners to extend therapy value beyond delivery. The platform will support use cases from clinical trials through commercialization phases.

The system will capture adherence data and patient-reported outcomes remotely, storing information securely and providing analytics dashboards for actionable insights. The modular design allows pharmaceutical partners to integrate digital components based on specific program needs.

"The enFuse companion solution reflects our vision of a more connected treatment experience that supports patients beyond the moment of injection," said Michael D. Hooven, Chairman and CEO of Enable Injections.

Damien McKeon, SVP Strategic Partnerships at Aptar Digital Health, stated that large-volume biologic therapies often require long-term adherence for optimal outcomes and digital solutions can help address common self-administration challenges.

Aptar Digital Health is part of AptarGroup (NYSE: ATR), which employs 14,000 people across 20 countries. Cincinnati-based Enable Injections develops the enFuse on-body drug delivery system for subcutaneous administration of large-volume pharmaceuticals and biologics.